)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Inovio Pharmaceuticals (INO) investor relations material
Inovio Pharmaceuticals H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 27th Annual Global Investment Conference summary5 Sep, 2025
Company overview and strategic focus
Focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with a deep pipeline and multiple near- and mid-term catalysts expected.
Lead program INO-3107 targets recurrent respiratory papillomatosis (RRP), a rare HPV-related disease, and is on the FDA's accelerated approval pathway.
Commercial-scale manufacturing for DNA plasmids is established, and next-generation technologies are in early development.
Top priority is the Biologics License Application (BLA) submission for INO-3107, with FDA agreement on a rolling submission timeline.
Eight additional clinical-stage candidates are in the pipeline, including other HPV, cancer, and DMAP programs.
Clinical trial results and regulatory progress
INO-3107 showed a statistically significant reduction in surgeries for RRP patients, with a median drop from four to one surgery in 12 months.
Durability extension trial confirmed continued reduction in surgeries into the second and third years, with over 75% reduction compared to pre-treatment.
81% of patients had at least one fewer surgery, and 72% had a 50% or greater reduction in surgeries in the first year.
28% of patients were surgery-free in year one, increasing to 50% in year two.
BLA submission is on track for completion in the second half of the year, with file acceptance targeted by year-end.
Market opportunity and product positioning
RRP affects an estimated 14,000 patients in the U.S., with similar prevalence in Europe; repeated surgeries can cause irreversible vocal cord damage.
INO-3107 is positioned as a preferred product due to efficacy, tolerability, and a simple, patient-centric treatment approach.
Physicians value the high rate of 50%-100% reduction in surgeries, and the treatment is well tolerated.
Can be administered in-office, with no need for scoping or minimal residual disease surgeries during dosing.
Launch preparations are advanced, with a focused field force and established distribution strategy.
Detail 3107's edge over new RRP therapy.
Outline dMAb partnership and next clinical steps.
Explain the long-term value of 3107 redosing.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Inovio Pharmaceuticals earnings date
Q3 202513 Nov, 2025
Next Inovio Pharmaceuticals earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Inovio Pharmaceuticals Inc is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines. The company’s research areas include infectious diseases, cancer immunotherapy, and rare diseases. Inovio develops DNA-based immunotherapies and vaccines delivered through its proprietary platform. The company is headquartered in Plymouth Meeting, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage